These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2363856)

  • 21. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines.
    Yamanaka T; Shiraki K; Sugimoto K; Ito T; Fujikawa K; Ito M; Takase K; Moriyama M; Nakano T; Suzuki A
    Hepatology; 2000 Sep; 32(3):482-90. PubMed ID: 10960439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma.
    Sugiyama T; Sadzuka Y
    Clin Cancer Res; 1999 Feb; 5(2):413-6. PubMed ID: 10037191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy.
    Xu J; Zhou JY; Wu GS
    Cancer Res; 2006 Oct; 66(20):10092-9. PubMed ID: 17047073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
    Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
    Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
    Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
    Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tumor necrosis factor related apoptosis-inducing ligand induces apoptosis and sensitizes resistant hepatic cancer cells to chemotherapy].
    He SQ; Chen XP; Zhang WG; Wang HP; Wang Q
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):456-9. PubMed ID: 15329202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antitumor activity and toxicity of combined doxorubicin and disodium salt of methylene-1,1-diphosphonic acid].
    Stukov AN; Mironiuk TN; Kon'kov SA; Krylova IM; Reztsova VV; Filov VA; Ivin BA
    Vopr Onkol; 1998; 44(1):100-2. PubMed ID: 9578741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
    de Wilt JH; Soma G; ten Hagen TL; Kanou J; Takagi K; Nooijen PT; Seynhaevel AL; Eggermont AM
    Anticancer Res; 2000; 20(5B):3491-6. PubMed ID: 11131652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors.
    Nakamoto T; Inagawa H; Takagi K; Soma G
    Anticancer Res; 2000; 20(6A):4087-96. PubMed ID: 11131677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
    Yoshida M; Maehara Y; Sugimachi K
    Clin Cancer Res; 1999 Dec; 5(12):4295-300. PubMed ID: 10632373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effect of recombinant human tumor necrosis factor alpha on malignant tumors in vivo. Physiopathologic basis for clinical oncology].
    Kallinowski F; Schaefer C; Tyler G; Möhle R; Vaupel P
    Arzneimittelforschung; 1989 Mar; 39(3):410-4. PubMed ID: 2757667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Degradable starch microspheres in cytostatic treatment of a liver carcinoma; experimental studies in rats with 5-fluorouracil, tauromustine, carmustine, doxorubicin and RSU-1069.
    Roos G; Christensson PI; el Hag IA; Jakobsson B; Teder H; Stenram U
    Anticancer Res; 1993; 13(3):635-41. PubMed ID: 8317891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
    van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
    Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
    Vadgama JV; Wu Y; Shen D; Hsia S; Block J
    Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.
    Palladino MA; Shalaby MR; Kramer SM; Ferraiolo BL; Baughman RA; Deleo AB; Crase D; Marafino B; Aggarwal BB; Figari IS
    J Immunol; 1987 Jun; 138(11):4023-32. PubMed ID: 3295044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Schedule-dependent enhanced lethality with combined administration of actinomycin D and tumor necrosis factor in mice.
    Buckley NJ; Walther PJ; Das AK; Poulton SH
    J Biol Response Mod; 1989 Jun; 8(3):287-96. PubMed ID: 2746299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.